Although experimental randomized prospective studies show that insulin therapy can be safe and efficacious in improving glycemic control in T2DM [15, 23, 24], little is known about factors associated with switching from noninsulin to insulin therapy in routine practice. The gene discussed is INS; the disease is type 2 diabetes mellitus.